IXICO PLC (DE:PYPB)
FRANKFURT:PYPB
PYPB Stock Chart & Stats
€0.13
<€0.01(0.75%)
At close: 4:00 PM EST
€0.13
<€0.01(0.75%)
Day’s Range― - ―
52-Week Range€0.07 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)87.00
Market Cap
€21.80M
Enterprise Value€6.93M
Total Cash (Recent Filing)€1.68M
Total Debt (Recent Filing)€559.00K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Dec 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,047,590
10 Day Avg. Volume262
30 Day Avg. Volume87
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€85.75K
Bulls Say, Bears Say
Bulls Say
Record Order Book & Revenue VisibilityAn £18.1m order book that provides ~95% coverage of FY26 guidance materially raises medium-term revenue visibility. This durable backlog supports planning, staffing, and capital allocation, reduces quarter-to-quarter volatility and improves the probability of converting pipeline into contracted revenue and margins over the next 2–6 months.
Improved Gross Margins And Operational LeverageA 53% gross margin reflecting more Phase II/III work and automated analysis shows the business is exploiting scalable, higher-value workflows. Sustained margin expansion from mix and automation supports conversion of revenue growth into operating leverage, improving the structural path to profitability if volume and mix are maintained.
Strategic Medidata Partnership Enabling ScaleIntegration with Medidata's Rave platform creates a durable distribution channel into sponsors and CROs running FDA programs. This partnership lowers go-to-market friction, accelerates adoption of productized analytics, and supports a structural shift toward recurring SaaS/licensing revenue and larger, platform-based contracts over time.
Bears Say
Persistent Losses And Weak Cash GenerationOngoing net losses and negative operating cash flow limit the company's ability to self-fund TechBio productization and commercial expansion. Reliance on external capital increases dilution and execution risk; until consistent positive cash generation occurs, balance sheet and funding remain structural constraints on growth.
Long TechBio Productization & Regulatory TimelineThe TechBio roadmap requires significant productization and an 18–24+ month regulatory path to software-as-a-medical-device. This delays recurring SaaS revenue and creates multi-year execution and certification risk, meaning the structural benefits of scaled, predictable revenue won't materially support cash flow in the near term.
Trial Cancellation Exposure & Concentration RiskAs an imaging CRO, revenue is exposed to trial descopes/cancellations, which can cause abrupt revenue loss and margin disruption. Combined with uneven conversion of pipeline interest (Alzheimer’s ~50% pipeline but only ~20% of order book), this structural exposure makes revenue diversification and predictability a persistent challenge.
IXICO plc News
PYPB FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest stock price was €0.07 and its highest was €0.15 in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is €21.80M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is Dec 08, 2026 which is in 186 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on May 19, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 218,047,590 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in DE:PYPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---